Welcome to Cardiology Today – Recorded October 27, 2025. This episode summarizes 5 key cardiology studies on topics like hypertensive disorders of pregnancy and pathogenic variant. Key takeaway: Trimetazidine for Early Hypertrophic Cardiomyopathy. Article Links: Article 1: Recaticimab in adult heterozygous familial hypercholesterolaemia (REMAIN-3): a multicentre, randomized, double-blind, placebo-controlled Phase 3 study. (Cardiovascular research) Article 2: Effects of iron deficiency anaemia on maternal haemodynamics and cardiac function in pregnant spontaneously hypertensive rats. (Cardiovascular research) Article 3: The pioneer factor, ETV2, regulates networks to specify the embryonic endothelial lineage. (Cardiovascular research) Article 4: YY1 regulates vascular resistance and blood pressure dynamics through epigenetic control of m6A RNA modifications in vascular smooth muscle cells. (Cardiovascular research) Article 5: Effect of trimetazidine dihydrochloride therapy on myocardial external efficiency in pre-clinical individuals with a hypertrophic cardiomyopathy pathogenic variant: results of the ENERGY trial. (Cardiovascular research) Full episode page: https://podcast.explainheart.com/podcast/trimetazidine-for-early-hypertrophic-cardiomyopathy-10-27-25/ Featured Articles Article 1: Recaticimab in adult heterozygous familial hypercholesterolaemia (REMAIN-3): a multicentre, randomized, double-blind, placebo-controlled Phase 3 study. Journal: Cardiovascular research PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40911402 Summary: The REMA.I.N.-3 study was a multicenter, randomized, double-blind, placebo-controlled Phase 3 trial. It assessed the efficacy and safety of recaticimab, a new humanized anti-Proprotein Convertase Subtilisin/Kexin type 9 antibody. This drug targets reduction of low-density lipoprotein cholesterol levels in adults with poorly controlled heterozygous familial hypercholesterolaemia. This research provides crucial data regarding a potential new therapeutic agent for this genetic disorder. Article 2: Effects of iron deficiency anaemia on maternal haemodynamics and cardiac function in pregnant spontaneously hypertensive rats. Journal: Cardiovascular research PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40878014 Summary: This study investigated the effects of iron deficiency anemia on maternal hemodynamics and cardiac function during pregnancy. Researchers utilized pregnant spontaneously hypertensive rats and normotensive controls to understand how iron deficiency interacts with hypertensive disorders of pregnancy. This research is critical for determining whether iron deficiency ameliorates or exacerbates maternal cardiovascular dysfunction in these high-risk pregnancies. Establishing this relationship could inform better management strategies for pregnant patients. Article 3: The pioneer factor, ETV2, regulates networks to specify the embryonic endothelial lineage. Journal: Cardiovascular research PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40832854 Summary: This study elucidated the role of E.T.V.2, a pioneer transcription factor, in specifying the embryonic endothelial lineage. Researchers uncovered the specific transcriptional and epigenetic changes orchestrated by E.T.V.2 to promote hematoendothelial lineage development. Concurrently, E.T.V.2 was shown to suppress other mesodermal cell fates, precisely directing differentiation. This fundamental research significantly advances our understanding of cardiovascular development and lineage specification, offering potential avenues for regenerative strategies. Article 4: YY1 regulates vascular resistance and blood pressure dynamics through epigenetic control of m6A RNA modifications in vascular smooth muscle cells. Journal: Cardiovascular research PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40795179 Summary: modifications in vascular smooth muscle cells. This study established that the transcription factor Y.Y.1 directly regulates vascular resistance a